We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

QuidelOrtho

Develops, manufactures and markets rapid diagnostic tests that focus on infectious diseases, reproductive health, and... read more Featured Products: More products

Download Mobile App





QuidelOrtho Highlights Innovative Point-of-Care Diagnostic Solutions

By LabMedica International staff writers
Posted on 21 May 2023

QuidelOrtho Corporation (San Diego, CA, USA) is highlighting the latest advances in laboratory testing and point-of-care diagnostics at the Euromedlab Congress in Rome. More...

The company is demonstrating how effectively combining point-of-care and laboratory testing can enhance patient care and improve overall healthcare outcomes. QuidelOrtho’s advanced lab management tools and expertise can help labs streamline their workflow, automate operations, and efficiently analyze data, thereby enhancing overall efficiency without compromising on quality.

At EuroMedLab Rome 2023, the company is demonstrating Savanna – a true sample-to-result point-of-care multiplex molecular solution. The cutting-edge system can accurately and simultaneously test for SARS-CoV-2, Flu A, Flu B, and RSV on a panel within 20 minutes. Besides delivering rapid results, the RVP4 also delivers superior clinical performance and possesses the capability to detect SARS-CoV-2 variants. Additionally, QuidelOrtho is demonstrating how its Vitros XT 7600 Integrated System can boost lab efficiency, offering a wide-ranging menu of over 160 assays, thus future-proofing labs and preparing them for potential Vitros Automation incorporation. This system is also time-efficient, with a first-pass yield of 96.5% and incorporates E-Connectivity Technology for uninterrupted operation. The company's innovative waterless system further maximizes lab space and enhances productivity.

Among QuidelOrtho’s innovative point-of-care solutions being featured at the industry event is the TriageTrue High Sensitivity Troponin I Test. This revolutionary test empowers medical professionals to make informed decisions that lead to better patient outcomes and overall improved healthcare efficiency. The test merges ER and lab testing, delivering high diagnostic precision with results available in under 20 minutes. The quick results can expedite patient handling, minimize hospital stay duration, and enhance ED throughput. In addition, QuidelOrtho is participating in the Euromedlab 2023 Satellite Meeting - Point-of-Care Testing: Home, Hospital and Beyond event. The company’s Vendor Talk by Dr. Holger Gundelach, Head of EMEA POC-IA Business Unit and Clinical Value at QuidelOrtho, on "The time is now – Accelerate patient management at the point-of-care" will be providing valuable insights and exploring the future of point-of-care testing.

Related Links:
QuidelOrtho Corporation 


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Serological Pipet Controller
PIPETBOY GENIUS
New
See-Saw Rocking Shaker
SH-200D-S-L
New
Biochemistry Analyzer
Chemi+ 8100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.